Silverarc Capital Management, LLC Crinetics Pharmaceuticals, Inc. Transaction History

Silverarc Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$34.76 - $46.81 $4.44 Million - $5.98 Million	127,835 New	127,835 $5.98 Million
Q3 2023 Nov 13, 2023	BUY	$15.97 - $30.59 $3.51 Million - $6.73 Million	220,000 New	220,000 $6.54 Million
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $57,622 - $70,866	3,720 Added 2.5%	152,747 $2.8 Million
Q3 2022 Oct 28, 2022	BUY	$18.11 - $22.37 $171,827 - $212,246	9,488 Added 6.8%	149,027 $2.93 Million
Q2 2022 Jul 25, 2022	BUY	$16.49 - $27.64 $421,072 - $705,787	25,535 Added 22.4%	139,539 $2.6 Million
Q1 2022 May 13, 2022	BUY	$17.15 - $28.31 $36,769 - $60,696	2,144 Added 1.92%	114,004 $2.5 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $1.21 Million - $1.77 Million	62,478 Added 126.52%	111,860 $3.18 Million
Q3 2021 Nov 15, 2021	BUY	$16.88 - $25.23 $833,568 - $1.25 Million	49,382 New	49,382 $1.04 Million

241

80M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.12B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.